System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
US11385229B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11385229-B2 |
| Application number | US-201916541111-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 14, 2019 |
| Priority date | Feb 20, 2017 |
| Publication date | Jul 12, 2022 |
| Grant date | Jul 12, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Diagnostic assays and methods employ a dual-enzyme cascade system comprised of two enzymatic amplifiers and two molecular probes, by (a) incubating a target enzyme with a target enzyme substrate to liberate a thiol; (b) incubating the thiol with a disulfide inactivated amplification enzyme to activate the amplification enzyme in an interchange reaction of the thiol and the disulfide; and (c) incubating the activated amplification enzyme with an amplification enzyme substrate to generate an amplified signal.
Opening claim text (preview).
The invention claimed is: 1. An assay method to determine the presence of a β-lactam resistant bacterium in a sample from a subject, the method comprising: obtaining the sample from the subject; incubating the sample with reaction components comprising: (i) a β-lactamase probe having a structure selected from the group consisting of: (ii) papain-S—S—CH 3 ; and (iii) a papain probe having a structure selected from the group consisting of: and determining the generation of a colorimetric signal from incubating the sample with the reaction components by visual inspection of the sample or by absorption spectroscopy, wherein the absorption spectroscopy is carried out at a wavelength of 405 nm; wherein, the colorimetric signal which has been generated from the incubated sample indicates that the subject's sample comprises a β-lactam resistant bacterium, wherein the sample that is obtained from the subject is an unprocessed urine sample, wherein the unprocessed urine sample is obtained from a subject that has, or is suspected of having, a urinary tract infection, and wherein the sample is incubated with the reaction components at room temperature.
for enzymes or isoenzymes · CPC title
involving hydrolase · CPC title
involving oxidoreductase · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.